Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (331-340 of 349) with videos related to

Pageof 35
Sort By:
European Urology Oncology|March 3, 2023
Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate CancerAli Sabbagh, Samuel L Washington, Derya Tilki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancerAndrew J Armstrong, George J Netto, Michelle A Rudek, et al.
Oncotarget|December 22, 2017
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomyAshley E Ross, Robert M Hughes, Stephanie Glavaris, et al.
The Journal of Urology|March 23, 2011
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen rangeWilliam J Catalona, Alan W Partin, Martin G Sanda, et al.
The Journal of Urology|December 5, 2012
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibrationStacy Loeb, Lori J Sokoll, Dennis L Broyles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.
The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2015
¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate CancerSteven P Rowe, Kenneth L Gage, Sheila F Faraj, et al.
European Urology|August 3, 2012
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assayJens Hansen, Marco Auprich, Sascha A Ahyai, et al.
The Journal of Urology|August 26, 2021
Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 ConsortiumPeter Chang, Andrew A Wagner, Meredith M Regan, et al.
Pageof 35

Showing results (331-340 of 349) with videos related to

Sort By:
Pageof 35
European Urology Oncology|March 3, 2023
Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate CancerAli Sabbagh, Samuel L Washington, Derya Tilki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2010
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancerAndrew J Armstrong, George J Netto, Michelle A Rudek, et al.
Oncotarget|December 22, 2017
Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomyAshley E Ross, Robert M Hughes, Stephanie Glavaris, et al.
The Journal of Urology|March 23, 2011
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen rangeWilliam J Catalona, Alan W Partin, Martin G Sanda, et al.
The Journal of Urology|December 5, 2012
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibrationStacy Loeb, Lori J Sokoll, Dennis L Broyles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2020
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate CancerAleksandar Z Obradovic, Matthew C Dallos, Marianna L Zahurak, et al.
The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 13, 2015
¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate CancerSteven P Rowe, Kenneth L Gage, Sheila F Faraj, et al.
European Urology|August 3, 2012
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assayJens Hansen, Marco Auprich, Sascha A Ahyai, et al.
The Journal of Urology|August 26, 2021
Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 ConsortiumPeter Chang, Andrew A Wagner, Meredith M Regan, et al.
Pageof 35